Basilea Pharmaceutica AG (OTCMKTS:BPMUF) Sees Significant Decrease in Short Interest

Basilea Pharmaceutica AG (OTCMKTS:BPMUF) was the target of a significant decline in short interest in March. As of March 15th, there was short interest totalling 2,100 shares, a decline of 86.6% from the February 28th total of 15,700 shares. Based on an average daily trading volume, of 100 shares, the days-to-cover ratio is presently 21.0 days. Currently, 0.0% of the company’s stock are sold short.

Basilea Pharmaceutica Price Performance

OTCMKTS:BPMUF remained flat at $54.00 during trading hours on Thursday. Basilea Pharmaceutica has a 1-year low of $38.60 and a 1-year high of $54.00. The company has a quick ratio of 3.27, a current ratio of 4.10 and a debt-to-equity ratio of 5.70. The company has a 50 day simple moving average of $52.90 and a two-hundred day simple moving average of $52.59.

About Basilea Pharmaceutica

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.